Quoin Reports Clinically Meaningful Whole Body Response to QRX003 in Pediatric Netherton Syndrome; Second Patient Cleared for Dosing
Initial pediatric subject shows sustained benefit with QRX003; second patient approved for full-body treatment in ongoing ...
The Manila Times12d
Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases
Target Indications Also Include Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma and Severe Atopic Dermatitis; ...
Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
Detailed price information for Quoin Pharmaceuticals Ltd ADR (QNRX-Q) from The Globe and Mail including charting and trades.
Frontiers29d
Case Report: Successful management of refractory palmoplantar pustulosis with upadacitinib
Throughout the treatment, clinical symptoms and the patient’s quality of life were assessed using the Palmoplantar Pustular Psoriasis Area and Severity Index (PPP ASI), the Palmoplantar Pustulosis ...